Conmed (CNMD)
NYSE:CNMD
Want to see CNMD full AI Analyst Report?
CNMD Stock Chart & Stats
$44.35
$0.19(0.28%)
At close: 4:00 PM EST
$44.35
$0.19(0.28%)
Day’s Range― - ―
52-Week Range$32.13 - $60.35
Previous CloseN/A
Volume49.43K
Average Volume (3M)368.83K
Market Cap
$1.06B
Enterprise Value$1.90B
Total Cash (Recent Filing)$35.03M
Total Debt (Recent Filing)$860.87M
Price to Earnings (P/E)19.6
Beta0.68
Next Earnings
Jul 29, 2026EPS Estimate
1.11Next Dividend Ex-DateN/A
Dividend Yield2.02%
Share Statistics
EPS (TTM)1.77
Shares Outstanding30,109,194
10 Day Avg. Volume284,080
30 Day Avg. Volume368,831
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)1.22
Price to Sales (P/S)0.92
P/FCF Ratio8.35
Enterprise Value/Market Cap1.80
Enterprise Value/Revenue1.39
Enterprise Value/Gross Profit2.59
Enterprise Value/Ebitda8.99
Forecast
1Y Price Target
$39.39Price Target Upside-11.18% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)4.36
Revenue Forecast (FY)$1.36B
Bulls Say, Bears Say
Bulls Say
AirSeal Installed Base And Large TAMA >10k installed base with low U.S. penetration implies a durable multi-year growth runway for systems and consumable pull-through. Large procedure volumes create recurring revenue potential, supporting sustained adoption and margin expansion if AirSeal captures incremental share over time.
Recurring Consumables And Installed-base Pull‑throughA business mix of capital equipment plus procedure-linked consumables produces recurring, volume-tied revenue. Durable consumable pull-through smooths revenue visibility, supports higher gross margins long-term, and makes growth less dependent on one-time equipment sales.
Proactive Debt Refinancing And Convertible RepurchaseRetiring most convertibles and securing a term loan materially reduces dilution risk and improves funding flexibility. Lower future interest and fewer conversion liabilities strengthen capital structure, supporting strategic investments and sustaining buybacks with less refinancing uncertainty.
Bears Say
Sharp TTM Revenue Decline And Compressed MarginsA roughly 30% TTM sales drop and materially compressed net margin substantially weaken earnings quality. Such revenue erosion reduces scale benefits, limits reinvestment capacity, and raises the bar for management to restore durable growth and return on equity absent sustained organic recovery.
Weaker Operating Cash Flow And Higher Working CapitalA sharp drop in quarterly operating cash and deliberate inventory build increased receivable and inventory days, straining cash conversion. Persistently higher working capital can hamper FCF generation, reduce buffer for refinancing, and limit the firm's ability to invest or repurchase shares sustainably.
Elevated Leverage And Refinancing-related Interest BurdenHigher gross leverage and a planned bank refinancing that increases interest costs elevate fixed finance obligations. This reduces flexibility for M&A or R&D, raises breakeven operating requirements, and can compress free cash flow and EPS until deleveraging or margin recovery occurs.
Conmed News
CNMD FAQ
What was Conmed’s price range in the past 12 months?
Conmed lowest stock price was $32.13 and its highest was $60.35 in the past 12 months.
What is Conmed’s market cap?
Conmed’s market cap is $1.06B.
When is Conmed’s upcoming earnings report date?
Conmed’s upcoming earnings report date is Jul 29, 2026 which is in 50 days.
How were Conmed’s earnings last quarter?
Conmed released its earnings results on Apr 29, 2026. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.819 by $0.071.
Is Conmed overvalued?
According to Wall Street analysts Conmed’s price is currently Overvalued.
Does Conmed pay dividends?
Conmed pays a Quarterly dividend of $0.2 which represents an annual dividend yield of 2.02%. See more information on Conmed dividends here
What is Conmed’s EPS estimate?
Conmed’s EPS estimate is 1.11.
How many shares outstanding does Conmed have?
Conmed has 30,109,194 shares outstanding.
What happened to Conmed’s price movement after its last earnings report?
Conmed reported an EPS of $0.89 in its last earnings report, beating expectations of $0.819. Following the earnings report the stock price went up 1.947%.
Which hedge fund is a major shareholder of Conmed?
Currently, no hedge funds are holding shares in CNMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Conmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$39.39 (-11.18% Downside)
$39.39 (-11.18% Downside)
Hedge Fund Trend
Increased
By 264.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.21%
12-Months-Change
Fundamentals
Return on Equity
5.40%
Trailing 12-Months
Asset Growth
0.75%
Trailing 12-Months
Company Description
Conmed
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
CNMD Company Deck
CNMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive view: near‑term headwinds included modest revenue declines on a reported basis, lower adjusted net income and EPS, weaker cash from operations and higher working capital as inventory was intentionally built. Offsetting these concerns were upgraded organic revenue guidance (5.0%–6.5%), clear momentum in core growth platforms (AirSeal, Buffalo Filter direct smoke, BioBrace), improved gross margin (up 100 bps) and maintained full‑year adjusted EPS guidance despite a planned refinancing headwind. Management also completed GI divestitures to focus resources and continued buybacks. Overall the transcript shows cautious optimism with tangible operational and strategic progress balanced against short‑term financial pressures.View all CNMD earnings summariesCNMD Stock 12 Month Forecast
Average Price Target
$39.39
▼(-11.18% Downside)
Technical Analysis
Artivion
―
Integra Lifesciences
―
Ufp Technologies
―
AdaptHealth
―
PROCEPT BioRobotics
―
Ownership Overview
0.19% Insiders
38.45% Mutual Funds
31.72% Other Institutional Investors
0.40% Public Companies and
Individual Investors